Scientists create mimic of 'good' cholesterol to fight heart disease and stroke

October 10, 2014, The Scripps Research Institute
Authors of the new study include Scripps Research Institute Professor Reza Ghadiri (center), Assistant Professor of Chemistry Luke Leman (right) and Research Associate Yannan Zhao

Scientists at The Scripps Research Institute (TSRI) have created a synthetic molecule that mimics "good" cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks.

This research, published in the October issue of Journal of Lipid Research, points scientists toward a new method for treating atherosclerosis, a condition where in the arteries can cause heart attacks and strokes.

"Atherosclerosis is the number one killer in the developed world," said TSRI Professor M. Reza Ghadiri, senior author of the new study with TSRI Assistant Professor of Chemistry Luke Leman. "This research clears a big step toward clinical implementation of new therapies."

Good vs. Bad Cholesterol

To combat atherosclerosis, researchers are looking for new ways to target and remove low-density lipoprotein (LDL) cholesterol (commonly known as "bad" cholesterol) from the body. Though the body needs some LDL to stay healthy, high levels lead to dangerous plaque buildups. In contrast, (HDL) cholesterol ("good" cholesterol) is known for its protective effects.

"HDL is like a taxi in the bloodstream; it takes the LDL cholesterol out of the blood and delivers it to the liver," said Yannan Zhao, a postdoctoral researcher in Ghadiri's lab and first author of the new study. From the liver, the LDL is packaged for elimination from the body.

Using a method reported by the researchers last year in the Journal of the American Chemical Society, the team created a "nanopeptide" to have three arm-like structures that can wrap around cholesterol and fats in the blood.

Once the wraps around LDL cholesterol, it removes it by mimicking the behavior of apoA-1, a protein of HDL, and carrying it to the liver for elimination.

A Surprising Finding

In collaboration with Linda Curtiss, formerly a faculty member at TSRI, and Bruce Maryanoff, formerly at Johnson & Johnson and currently a visiting scholar at TSRI, the researchers tested this synthetic peptide in a mouse model prone to atherosclerosis.

The team originally used the synthetic peptide in an experiment the researchers thought was a gamble. They gave it to mice in their drinking water, but assumed their digestive acids might break down the peptide before it got a chance to interact with its target and modify LDL cholesterol. To their surprise, it worked.

After 10 weeks of treatment, the mice had a 40 percent reduction in potentially harmful cholesterol in their blood and a 50 percent reduction in the size of plaque lesions in their hearts.

"We were definitely surprised at the results in the oral feeding studies," said Leman. "We've repeated it many times."

Many treatments currently in development rely on an injection, not a pill. With the option of an orally effective peptide, Ghadiri believes researchers are closer to developing an accessible new therapy for .

The researchers also reported no signs of increased inflammation in the blood or toxicity after 10 weeks of the peptide treatment.

Future Studies Point to Gut

Ghadiri and his team are now investigating exactly how the synthetic peptide works in the intestines and the possibility that it interacts with beneficial microbes. The researchers believe that finding new targets in the gastrointestinal tract could lead to new therapies for many more diseases.

"That's one of the fun things in science—now we get to follow up on these different avenues," said Leman.

Explore further: Genetically engineered tomatoes decrease plaque build-up in mice

More information: "In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I" J. Lipid Res. 2014 55:(10) 2053-2063. DOI: 10.1194/jlr.M049262

"Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?" J. Lipid Res. 2014 55:(10) 1983-1985. DOI: 10.1194/jlr.E053538

Related Stories

Genetically engineered tomatoes decrease plaque build-up in mice

November 5, 2012
For the first time, genetically engineered tomato plants produced a peptide that mimics the actions of good cholesterol when eaten, researchers reported at the American Heart Association's Scientific Sessions 2012.

Early atherosclerotic plaques regress when cholesterol levels are lowered

February 27, 2014
Early but not advanced forms of atherosclerotic plaques in the vessel wall disappear when the levels of 'bad' cholesterol are lowered, according to a study in mice from Karolinska Institutet, Sweden. The findings, published ...

Oxidized LDL might actually be 'good guy'

September 4, 2014
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.

LDL cholesterol indicates an amino acid deficiency, researcher says

February 26, 2014
Low-density lipoprotein (LDL), the "bad cholesterol" that doctors consider a sign of potential heart disease, is merely a marker of a diet lacking all of the essential amino acids, says University of Illinois comparative ...

Protein in 'good cholesterol' may be a key to treating pulmonary hypertension

August 27, 2014
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, ...

Recommended for you

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Gut hormone and brown fat interact to tell the brain it's time to stop eating

November 15, 2018
Researchers from Germany and Finland have shown that so-called "brown fat" interacts with the gut hormone secretin in mice to relay nutritional signals about fullness to the brain during a meal. The study, appearing November ...

Brain, muscle cells found lurking in kidney organoids grown in lab

November 15, 2018
Scientists hoping to develop better treatments for kidney disease have turned their attention to growing clusters of kidney cells in the lab. One day, so-called organoids—grown from human stem cells—may help repair damaged ...

How the Tasmanian devil inspired researchers to create 'safe cell' therapies

November 15, 2018
A contagious facial cancer that has ravaged Tasmanian devils in southern Australia isn't the first place one would look to find the key to advancing cell therapies in humans.

Researchers discover important connection between cells in the liver

November 15, 2018
University of Minnesota Medical School researchers have made a discovery which could lead to a new way of thinking about how disease pathogenesis in the liver is regulated, which is important for understanding the condition ...

Precision neuroengineering enables reproduction of complex brain-like functions in vitro

November 14, 2018
One of the most important and surprising traits of the brain is its ability to dynamically reconfigure the connections to process and respond properly to stimuli. Researchers from Tohoku University (Sendai, Japan) and the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.